Galectin Therapeutics (GALT)

• Market cap: $149M
• 1 day: 0%
• 5 days: -2.58%
• 1 month: -15.3%
• 3 months: -24.33%
• 6 months: -62.17%
• Year to date: -43.95%
• 1 year: 74.62%
• 5 years: -39.95%
• 10 years: 71.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 9